Background and Purpose: The optimal timing for starting oral anticoagulant after an
ischemic stroke related to atrial fibrillation remains a challenge, mainly in patients treated …

Strong evidence for the use of direct oral anticoagulants (DOACs) in the early phase of non
valvular atrial fibrillation (NVAF)-related acute ischemic stroke (AIS) is lacking, because this …

Background This meta-analysis aimed to evaluate the efficacy and safety of non-vitamin K
antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in secondary …

Ischemic stroke remains a major cause of mortality and morbidity in patients with atrial
fibrillation. The use of appropriate anticoagulants reduces the risk of ischemic stroke in these …

Background Patients with non‐valvular atrial fibrillation (NVAF) and previous stroke have a
significantly higher risk of stroke recurrence. This study aimed to examine the safety and …

Direct oral anticoagulants (DOACs) have revolutionized the field of anticoagulation in the
last decade, mainly due to their fixed dosing, rapid onset of anticoagulant effect, and non …

Patients with atrial fibrillation (AF) and ischemic stroke are at high risk for stroke recurrence.
Early anticoagulation may reduce the risk of recurrent events but is usually avoided due to …

Background Few studies focused on the functional outcomes of patients at 3 months after
receiving intravenous thrombolysis, anticoagulation, or antiplatelet therapy within 4.5 h of …

Purpose There are various patterns in determining the choice of the first-line antithrombotic
agent for acute stroke with non-valvular atrial fibrillation. We investigated the efficacy and …

Περίληψη Σκοπός της παρούσας εργασίας είναι να παρουσιάσει την τρέχουσα κατάσταση της
γνώσης σχετικά με την Ενδοφλέβια θρομβόλυση σε ασθενείς με προηγούμενη …